Indeed, a wide range of studies and clinical trials have been performed to modulate KP enzyme activities as cancer therapeutic strategies, mainly related to IDO1, TDO2, KAT and KYNU, that are too numerous to list here, but the following are useful reviews and accounts [75,101,125–128]. The gene discussed is TDO2; the disease is cancer.